We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

C-Reactive Protein Point-Of-Care Test Evaluated

By LabMedica International staff writers
Posted on 27 Aug 2019
Print article
Image: The cobas b 101 POC system; an in vitro diagnostic (IVD) test system offering C-reactive protein, HbA1c and a complete lipid profile (CHOL, HDL, LDL, TG) on one device at the point of care (Photo courtesy of Roche Diagnostics).
Image: The cobas b 101 POC system; an in vitro diagnostic (IVD) test system offering C-reactive protein, HbA1c and a complete lipid profile (CHOL, HDL, LDL, TG) on one device at the point of care (Photo courtesy of Roche Diagnostics).
C-reactive protein (CRP) is a key mediator of the acute-phase response, with blood levels of CRP increasing rapidly after an inflammatory stimulus. Therefore, changes in serum levels of CRP are a clinically useful marker of infection, inflammation, and tissue injury.

CRP testing in the primary setting as in point-of-care (POC) can help reduce diagnostic uncertainty by differentiating between bacterial and viral infections and has been shown to be cost-effective for reducing inappropriate antibiotic prescriptions. However, despite the availability of POC devices, POC CRP testing has not yet been widely adopted in primary care clinics.

Clinical laboratory scientists at the Catharina Hospital and Technical University Eindhoven (Eindhoven, The Netherland) and their colleagues evaluated a POC CPR test at three sites and one reference laboratory. Within-run (repeatability), within-laboratory (intermediate precision), and between-laboratory precision (reproducibility) were assessed. Method comparison and matrix/lot-to-lot comparison studies were conducted using prospectively collected blood samples from 217 adults (apparently healthy or with clinically relevant conditions).

The investigators compared the analytical performance of the cobas b 101 POC system, which provides glycated hemoglobin (HbA1c) and lipid panel tests (measurement of cholesterol, triglyceride, and high-density lipoprotein; calculation of low-density lipoprotein) for managing diabetes and dyslipidemia at point-of-need. This method was compared with a reference test: CRPNX reagent on a Roche cobas c 501 module.

The scientists reported that clinically relevant CRP concentrations measured with the CRP Test showed good agreement with those measured by CRPNX reagent. Coefficients of variation (CV) for repeatability and intermediate precision ranged from 1.7%–4.0% and 1.9%–4.5%, respectively, for human serum pools containing CRP 4.7–350.7 mg/L; repeatability in clinical samples ranged from 1.6%–5.9% (3.3–360.3 mg/L). CVs for reproducibility ranged from 2.5%–4.0% (4.7–344.3 mg/L). CRP concentrations were comparable for capillary whole blood, serum, Li-heparin whole blood/plasma, K2 and K3 EDTA whole blood/plasma. The overall mean usability score was 4.18/5 and the error rate across 9,378 tests was 1.00%.

The authors concluded that their findings indicate that healthcare professionals can obtain precise and reproducible CRP values with the cobas POC CRP Test that show very good correlation with laboratory measurements. Importantly, operators considered the system convenient for use in the POC environment. The study was published in the September 2019 issue of the journal Clinical Biochemistry.

Related Links:
Catharina Hospital and Technical University Eindhoven

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.